Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

TENX US Equity

Tenax Therapeutics, Inc.Health Care · Pharmaceutical Preparations · CIK 34956 · FY ends Dec 31
$1.90
+0.20 (+11.76%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-10as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on our consolidated financial statements.

Item 9A · ICFR · Based on its assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2025.

Item 9A · disclosure controls · Based on their evaluation, our President and Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2025, the end of the period covered by this Annual Report on Form 10-K, in that they provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC and is accumulated and communicated to our management, including our President and Chief Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

2024-12-312025-03-25as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on our consolidated financial statements.

Item 9A · ICFR · Based on its assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2024.

Item 9A · disclosure controls · Based on their evaluation, our President and Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2024, the end of the period covered by this Annual Report on Form 10-K, in that they provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC and is accumulated and communicated to our management, including our President and Chief Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

2023-12-312024-03-28as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on our consolidated financial statements.

Item 9A · ICFR · Based on its assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2023.

Item 9A · disclosure controls · Based on their evaluation, our President and Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2023, the end of the period covered by this Annual Report on Form 10-K, in that they provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC and is accumulated and communicated to our management, including our President and Chief Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

2022-12-312023-03-31as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on our consolidated financial statements.

Item 9A · ICFR · Based on its assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · Based on their evaluation, our President and Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2022, the end of the period covered by this Annual Report on Form 10-K, in that they provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC and is accumulated and communicated to our management, including our President and Chief Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

2021-12-312022-03-29as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are subject to litigation in the normal course of business, none of which management believes will have a material adverse effect on our consolidated financial statements.

Item 9A · ICFR · Based on its assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2021.

Item 9A · disclosure controls · Based on their evaluation, our President and Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021, the end of the period covered by this Annual Report on Form 10-K, in that they provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods required by the SEC and is accumulated and communicated to our management, including our President and Chief Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.